Extended Endocrine Therapy Predictive Validation: MA.17
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)–positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node–negative breast cancer patients. H/I was evaluated in MA.17 trial for prognostic performance for late recurrence and treatment benefit from extended adjuvant letrozole.1
Available free from Journal of the National Cancer Institute.
1.Sgroi DC et al. J Natl Cancer Inst. 2013; 105(14):1036-1042.
Download